Last €87.50 EUR
Change Today -0.148 / -0.17%
Volume 0.0
0MJA On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 3:19 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

mead johnson nutrition co (0MJA) Snapshot

Open
€88.94
Previous Close
€87.65
Day High
€89.44
Day Low
€87.50
52 Week High
01/23/15 - €90.53
52 Week Low
02/6/14 - €53.92
Market Cap
17.7B
Average Volume 10 Days
37.1
EPS TTM
--
Shares Outstanding
202.0M
EX-Date
12/11/14
P/E TM
--
Dividend
€1.37
Dividend Yield
1.30%
Current Stock Chart for MEAD JOHNSON NUTRITION CO (0MJA)

mead johnson nutrition co (0MJA) Details

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. Its infant formula products include formulas for routine feeding; solutions formulas for addressing mild feeding problems, such as gas/fussiness, soy formula, lactose intolerance, anti-regurgitation, and cow’s milk protein allergy risk; and specialty formula products, including formulas for addressing severe intolerance, formulas for premature and low birth weight infants, and medical nutrition products. Its children’s nutrition products comprise products for meeting children’s nutritional needs at one to three years of age, three to five years of age, and beyond five years of age. The company’s children’s nutrition products also include nutritionally-balanced milk supplements for children targeting nutritional needs during specific stages of development; powered milk supplements; and milk modifiers in powder form. It also produces a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers. The company markets its products primarily under the Enfamil Premium, Enfamil Premium Newborn, Enfamil A+, Enfalac A+, Enfapro A+, Enfamil Gentlease, Enfapro Premium, SanCor Bebé, SanCor Bebé Premium, Enfamil ProSobee, Enfamil LactoFree, Enfamil AR, Enfamil HA, Enfamil Comfort, Enfamil for Supplementing, Nutramigen, Nutramigen AA, Pregestimil, Enfamil Premature, Enfacare, Enfagrow, Enfagrow A+, Enfagrow Premium, Enfamil Human Milk Fortifier, Sustagen KID, Lactum, Alacta, ChocoMilk, and Cal-C-Tose brand names. It sells its products to mothers, health care professionals, and retailers in approximately 50 countries in North America, Europe, Asia, and Latin America. The company was founded in 1905 and is headquartered in Glenview, Illinois.

Founded in 1905

mead johnson nutrition co (0MJA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $893.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $603.8K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $548.0K
Senior Vice President and Secretary
Total Annual Compensation: $454.6K
Senior Vice President of Technical Operations
Total Annual Compensation: $377.3K
Compensation as of Fiscal Year 2013.

mead johnson nutrition co (0MJA) Key Developments

Mead Johnson Nutrition Company Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Mead Johnson Nutrition Company announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales of $1,094.2 million compared with $1,060.7 million for the same period a year ago. Earnings before interest and tax was $209.6 million compared with $203.9 million for the same period a year ago. Earnings before tax was $195.3 million compared with $192.2 million for the same period a year ago. Net earnings attributable to shareholders was $158.4 million or $0.78 per diluted share compared with $152.5 million or $0.75 per diluted share for the same period a year ago. Non GAAP, earnings before interest and income tax was $252.0 million compared with $227.5 million for the same period a year ago. Non GAAP, earnings before income tax was $237.7 million compared with $215.8 million for the same period a year ago. Non GAAP, net earnings attributable to shareholders was $186.2 million or $0.75 per diluted share compared with $167.2 million or $0.82 per diluted share for the same period a year ago. For the full year, the company reported net sales of $4,409.3 million compared with $4,200.7 million for the same period a year ago. Earnings before interest and tax was $988.3 million compared with $974.9 million for the same period a year ago. Earnings before tax was $928.0 million compared with $924.3 million for the same period a year ago. Net earnings attributable to shareholders was $719.8 million or $3.54 per diluted share compared with $683.8 million or $3.36 per diluted share for the same period a year ago. Net cash provided by operating activities was $793.4 million compared with $806.6 million for the same period a year ago. Payments for capital expenditures was $186.6 million compared with $240.4 million for the same period a year ago. Non GAAP, earnings before interest and income tax was $1,051.6 million compared with $1,008.1 million for the same period a year ago. Non GAAP, earnings before income tax was $991.3 million compared with $957.5 million for the same period a year ago. Non GAAP, net earnings attributable to shareholders was $759.4 million or $3.74 per diluted share compared with $714.7 million or $3.51 per diluted share for the same period a year ago. The company provided earnings guidance for the full year of 2015. The company look forward to continued success in 2015 and expects constant dollar revenue growth around 7%. As it enters 2015, its faces significant headwinds from a strengthening dollar. Approximately three quarters of revenue is in foreign currencies while much of its cost base is dollar denominated. As a result, its earnings are somewhat exposed to currency fluctuations. Lower commodity costs will, however, allow it to improve gross margins and invest incrementally behind its brands. The company expects 2015 non-GAAP EPS in the range of $3.90 to $4.00. The company expects reported sales growth to be approximately 3%, which includes adverse foreign exchange of 4%. Specified Items are currently expected to be $0.05 per diluted share excluding any MTMadjustments. As a result, full year GAAP EPS is expected to be in the range of $3.85 to $3.95.

Mead Johnson Nutrition Company to Report Q4, 2014 Results on Jan 29, 2015

Mead Johnson Nutrition Company announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Jan 29, 2015

Mead Johnson Nutrition Company, Q4 2014 Earnings Call, Jan 29, 2015

Mead Johnson Nutrition Company, Q4 2014 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0MJA:GR €87.50 EUR -0.148

0MJA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 3,976 INR 0.00
Inner Mongolia Yili Industrial Group Co Ltd CNY27.30 CNY -0.01
Perrigo Co PLC $151.74 USD -2.26
Hain Celestial Group Inc/The $52.77 USD -1.85
Yakult Honsha Co Ltd ¥7,180 JPY +40.00
View Industry Companies
 

Industry Analysis

0MJA

Industry Average

Valuation 0MJA Industry Range
Price/Earnings 30.4x
Price/Sales 4.7x
Price/Book 40.4x
Price/Cash Flow 30.3x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEAD JOHNSON NUTRITION CO, please visit www.mjn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.